Your browser doesn't support javascript.
loading
Considerations regarding maintenance therapy for acute myeloid leukemia in remission.
Schiller, Gary J; Kustanovich, Vlad.
Affiliation
  • Schiller GJ; Hematological Malignancy/Stem Cell Transplant Program, David Geffen School of Medicine at UCLA, Los Angeles, California, USA.
  • Kustanovich V; David Geffen School of Medicine at UCLA, Los Angeles, California, USA.
Expert Rev Anticancer Ther ; 24(1-2): 15-20, 2024.
Article de En | MEDLINE | ID: mdl-38230741
ABSTRACT

INTRODUCTION:

For most adult patients with acute myeloid leukemia, relapse is characteristic of the disease. When allotransplant in first complete remission is administered as consolidative therapy, relapse is still common, affecting 20-40% of recipients. Maintenance of remission with low-dose treatments may hold promise in preventing relapse. AREAS COVERED Improvements in the detection of clinical and biological variants of disease allow the practitioner to identify which patients, based on disease features, may benefit from therapy directed at residual clonal elements that might contribute to relapse. Along with improvements in methods of detecting residual disease, novel agents are under investigation as a platform in order to maintain remission and may contribute to prolonged survival. In this manuscript, we review literature available through PubMed regarding the use of maintenance therapy, described as post-remission or post-transplant treatment intended to delay or prevent relapse. EXPERT OPINION Although results of randomized studies are limited, a role for maintenance therapy, particularly directed at molecular targets, in distinct settings of post-remission management is recommended. We also advise that randomized studies of immune therapy along with opportunities for further evaluation of risk-agnostic interventions be a focus of cooperative groups.
Sujet(s)
Mots clés

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Leucémie aigüe myéloïde / Transplantation de cellules souches hématopoïétiques Type d'étude: Clinical_trials / Prognostic_studies Limites: Adult / Humans Langue: En Journal: Expert Rev Anticancer Ther Sujet du journal: NEOPLASIAS / TERAPEUTICA Année: 2024 Type de document: Article Pays d'affiliation: États-Unis d'Amérique Pays de publication: Royaume-Uni

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Leucémie aigüe myéloïde / Transplantation de cellules souches hématopoïétiques Type d'étude: Clinical_trials / Prognostic_studies Limites: Adult / Humans Langue: En Journal: Expert Rev Anticancer Ther Sujet du journal: NEOPLASIAS / TERAPEUTICA Année: 2024 Type de document: Article Pays d'affiliation: États-Unis d'Amérique Pays de publication: Royaume-Uni